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Abstract
Background: Country level comparisons of HIV prevalence among men having sex with men (MSM) is challenging
for a variety of reasons, including differences in the definition and measurement of the denominator group,
recruitment strategies and the HIV detection methods. To assess their comparability, self-reported data on HIV
diagnoses in a 2010 pan-European MSM internet survey (EMIS) were compared with pre-existing estimates of HIV
prevalence in MSM from a variety of European countries.
Methods: The first pan-European survey of MSM recruited more than 180,000 men from 38 countries across Europe
and included questions on the year and result of last HIV test. HIV prevalence as measured in EMIS was compared
with national estimates of HIV prevalence based on studies using biological measurements or modelling
approaches to explore the degree of agreement between different methods. Existing estimates were taken from
Dublin Declaration Monitoring Reports or UNAIDS country fact sheets, and were verified by contacting the
nominated contact points for HIV surveillance in EU/EEA countries.
Results: The EMIS self-reported measurements of HIV prevalence were strongly correlated with existing estimates
based on biological measurement and modelling studies using surveillance data (R2=0.70 resp. 0.72). In most
countries HIV positive MSM appeared disproportionately likely to participate in EMIS, and prevalences as measured
in EMIS are approximately twice the estimates based on existing estimates.
Conclusions: Comparison of diagnosed HIV prevalence as measured in EMIS with pre-existing estimates based on
biological measurements using varied sampling frames (e.g. Respondent Driven Sampling, Time and Location
Sampling) demonstrates a high correlation and suggests similar selection biases from both types of studies. For
comparison with modelled estimates the self-selection bias of the Internet survey with increased participation of
men diagnosed with HIV has to be taken into account. For most countries self-reported EMIS prevalence is higher
than measured prevalence, which is likely due to a combination of different time points of measurement,
measurement errors for small sample sizes, different sampling methods, and an indicator-inherent overestimate of
prevalence among the untested fraction of MSM.
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Background
International comparison of HIV prevalence among men
who have sex with men (MSM) is challenging for a variety
of reasons. Firstly, the denominator for such data, i.e. the
absolute number of MSM in a given country, is unknown,
and random samples for MSM cannot be drawn. Esti-
mates on HIV prevalence among MSM thus are typically
based on convenience samples [1] e.g.; for reviews see also
[2-4]. Respective studies in post-industrialized countries
have used samples of gay, bisexual, and other MSM
recruited through virtual (such as websites or online social
networks), or traditional venues for MSM, such as bars,
sport-studios, etc. The different sampling frames that are
used lead to methodological differences that directly im-
pact the prevalence estimates and hence comparability.
For venue-based sampling methods, number and type of
venues may differ substantially within and between coun-
tries, and for snowball sampling methods like Respondent
Driven Sampling, type and size of social and sexual net-
works may heavily depend on the social, political, and cul-
tural acceptance of sexual minorities. On the other hand,
self-reported data from anonymous Internet convenience
samples are also subject to selection biases introduced
through the sampling methods. Relevant to all measure-
ment strategies is the size of the MSM population, which
is defined in a variety of ways. The size of the HIV positive
population depends on whether biological samples are
tested or HIV diagnoses are self-reported. UNAIDS has
suggested to use the proportion of those who have been
diagnosed with HIV among those who have been tested
for HIV as an indicator for HIV prevalence [5]. This
assumes that those who have not been tested for HIV have
the same HIV prevalence as those who have been tested,
and - if applied for self-reported prevalence - it neglects
those who have seroconverted since their last negative
HIV test.
Participants in open access community-recruited
Internet surveys are unlikely to be representative of the
MSM population in any country. Surveys addressing
sexual behaviour, sexually transmitted infections and
HIV can be expected to have a self-selection bias to-
wards men with a greater interest in sex and HIV, and of
gay community attached MSM, particularly those diag-
nosed with HIV [6]. The high variability in participation
rates in Internet surveys is probably related to external
factors such as access to the Internet, popularity of
Internet dating and contact sites often used to recruit
survey participants for MSM in different countries, dif-
ferent relative sizes of the respective MSM populations,
and other factors.
Participants of specific seroprevalence studies with for-
malized sampling frames like Time Location Sampling
[e.g. [7] in gay venues or Respondent Driven Sampling
[8] may be more representative of MSM attending such
settings than seroprevalence studies without such forma-
lized sampling frames, but still the claim to reach repre-
sentative samples of the whole MSM population with
these methods is unfounded, particularly because the ab-
solute size and composition of the MSM population
(which critically depends on the definition of MSM)
remains unknown. This is underlined by the observation
that repeated seroprevalence studies using such meth-
ods, e.g. in South-eastern European countries, some-
times result in declining seroprevalence estimates for
HIV [9,10], suggesting changing self-selection biases for
participation of men at risk for acquiring HIV over time.
Faced with the wide diversity of methods and approaches
to measure HIV prevalence, an unresolved question is,
whether and how data on HIV prevalence can be com-
pared between different countries and studies using differ-
ent methodologies.
To address this question, national data on HIV preva-
lence in the MSM population from a variety of Euro-
pean countries and using a variety of methodological
approaches were compared with self-reported data on
diagnosed HIV in survey participants of the first pan-
European MSM Internet survey (EMIS) conducted in
2010.
Methods
EMIS derived data
A detailed description of the survey methods will be pub-
lished elsewhere (a descriptive survey report including a
description of methods will become available on the pro-
ject website www.emis-project.eu in the first quarter
2013). Briefly, a network of five primary and 77 secondary
partners working in MSM sexual health across academia,
public health and community organizations in 38 Euro-
pean countries developed a collaborative English language
survey. The survey was translated into 24 other languages,
and prepared for administration on the Internet in a lan-
guage of the users’ choice. It was promoted through gay
online social media including PlanetRomeo, Manhunt,
and Gaydar, and through gay community organizations.
The survey was accessible online from June through August
2010. EMIS was approved by the Research Ethics Com-
mittee of the University of Portsmouth, United Kingdom
(REC application number 08/09:21).
Survey participants were asked whether they had ever
been tested for HIV, the result of their last test, and the
year of their first positive result or most recent negative
result. From these questions an indicator of HIV preva-
lence was constructed as recommended by WHO/
UNAIDS for UNGASS (indicator number 23) and Global
AIDS Response Progress reporting (indicator 1.14 [5,11])a:
HIV prevalence was defined as the proportion of
respondents diagnosed HIV positive among those ever
tested for HIV.
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Other HIV prevalence studies or estimates
We searched for HIV prevalence estimates and respect-
ive studies in the “Dublin Declaration Monitoring Re-
port” published by ECDC and WHO/Europe [12],
publications of other UN organisations [13], and on the
UNAIDS country fact sheets [14] based on the UNGASS
monitoring round in 2009.
(1) Prevalence estimates were derived from specific
prevalence studies (directly measured prevalence in
studies using venue-based, snowball or respondent
driven sampling,
(2) self-reports in community based surveys (internet,
bar/club or gay press recruited),
(3) calculated or modelled from the estimated total
number of MSM living with HIV (based on
surveillance data) and the estimated total size of the
MSM population (from national statistics and
general population surveys) using more or less
sophisticated approaches [15,16].
Most prevalence estimates could be verified and partly
updated by consulting the nominated contact pointsb for
HIV surveillance in the respective countries. Contact
points from 32 countries responded, except Austria,
Belorussia, Bulgaria, Croatia, Malta, and Moldova (for a
list of the countries see Table 1).
Comparison of prevalence study and survey derived
prevalence estimates
Because of unknown self-selection biases in both preva-
lence studies and internet based surveys, no adjust-
ments were made and prevalence study based estimates
were compared directly with the EMIS prevalence esti-
mate. If different prevalence estimates were available
from seroprevalence studies for the same country (e.g.
from different, not too distinct time points or different
areas) a median value was calculated. For the six city
SIALON study, which used time location sampling in
larger cities of six Mediterranean and Central European
countries [7], comparable regions were selected for the
EMIS prevalence estimates.
For all countries a survey-surveillance discrepancy
(SSD) factor was calculated by dividing the two preva-
lence rates derived from the EMIS survey and the preva-
lence studies: SSD=prevEMIS/prevstudy.
Comparison of modelling and survey-derived prevalence
estimates
For countries whose prevalence estimates were based on
modelling or calculations involving surveillance data, the
respective estimate of the relative or absolute size of the
MSM population was used in the following formula to
determine a survey-surveillance discrepancy (SSD) factor
to get a crude measure for the self-selection bias in the
Internet survey data:
SSD ¼
HIVEMIS
NEMIS
HIVpop
Npop
¼ SSD ¼ HIVEMIS
HIVpop
⋅
Npop
NEMIS
In this formula HIVEMIS is the number of survey parti-
cipants diagnosed with HIV, HIVpop is the estimated
number of HIV-infected MSM in the population, Npop is
the estimated total size of the MSM population (for the
countries with prevalence estimates based on modelled/
surveillance data – Germany, Denmark, Finland, Luxem-
burg, Netherlands, Norway, UK – the relative size of the
MSM population was assumed to be 3%, based on re-
spective data from general population surveys from
Germany and the UK), and NEMIS is the respective na-
tional sample size in EMIS.
For each country the SSD represents the ratio of sur-
vey members diagnosed with HIV to the total sample
size, divided by the ratio of the estimated number of
MSM infected with HIV in the total population to the
estimated total MSM population.
A value of 1 represents a country where survey data
and surveillance data match. Values below 1 are coun-
tries where fewer men in the survey were diagnosed
with HIV than would be expected from the surveillance
data-based model (i.e. men with diagnosed HIV are
under-represented in the survey, or over-represented in
the surveillance data), and values above 1 are the re-
verse (i.e. men with diagnosed HIV are overrepresented
in the survey, or underrepresented in the surveillance
data).
Results
A detailed description of the demographic characteristics
of the participants is available online in the EMIS Final
Report (accessible in early 2013 on www.emis-project.eu).
The proportion of the total population who partici-
pated in EMIS (participation rate) varied widely, from 3
to almost 70 per 100,000 (see Figure 1). As far as re-
sponse rates per recruiter website could be determined –
109,951 out of a total of 174,209 respondents were
recruited via personalized invitations from two supra-
national gay websites – differences in response rates
were much smaller, between 4% and 14% of those
invited to participate.
The proportion of EMIS participants who had ever
been tested for HIV varied between 43% in Lithuania
and 84% in France, the proportion of men with diag-
nosed HIV among those ever tested between 0% in
Bosnia-Herzegovina and 19.7% in the Netherlands (see
Table 1 and Additional file 1: Table S1).
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Table 1 National HIV prevalence data for MSM in European countries and corresponding self-reported prevalence data
from EMIS
Surveillance system EMIS
source of HIV prevalence
estimate; study
methodology
HIV prevalence
estimate; surveillance
system %
Diagnosed HIV+
among ever
tested (%)
Survey-Surveillance
Discrepancy factor
(SSD)
excluded, no surveillance
system prevalence
estimates
Austria n.a 7.2
Cyprus n.a. 1.9
Ireland n.a. 9.5
Malta n.a. 2.5
Turkey n.a. 3.0
excluded, similar
methodology
Belgium 2a 5.6 10.5
Switzerland 2a (2007) 8.1 11.5
France 2a (2009) 12.0 12.7
Sweden 2a (2008) 4.0 6.4
specific prevalence studies Bosnia 1b/c (<2008) 0.7 0.0
Bulgaria 2 3.3 2.5 0.7
Belarus 2 2.7 3.0 1.1
Czech 2b (2008/9) 2.6 6.7 2.6
Estonia 2c (2007) 1.7 2.8 1.7
Spain 2b (2008/9) 17.0 14.9 0.9
Croatia 2 3.3 4.8 1.5
Hungary 2 2.7 5.6 2.1
Italy 1b (2008/9) 11.8 10.7 0.9
Lithuania 2b 2.7 4.8 1.8
Latvia 2b (2008) 4.0 7.8 1.9
Moldowa 1b/c (2007) 4.8 4.3 0.9
Macedonia 2b/c (2006) 2.8 7.7 2.7
Poland 2b (2004) 4.7 8.3 1.8
Portugal 3a (snowball) 11.0 10.9 1.0
Romania 2b (2008/9) 4.6 5.5 1.2
Serbia 3b/c (2008/10) 3.6 5.4 1.5
Russia 2c 8.3 8.6 1.0
Slovenia 2b (2008/9) 5.1 8.3 1.6
Slovakia 2b (2008/9) 6.1 3.1 0.5
Ukraine 3b/c (2011) 6.4 8.2 1.3
modelling/ health care
system data
Germany 3e (2010) 4.9 11.6 2.4
Denmark 1d (2009) 4.9 12.0 2.4
Finland 3d (2009) 2.0 5.1 2.6
Greece 1d (EPP) 6.5 12.9 2.0
Luxemburg 3d (2010) 6.0 13.8 2.3
Netherlands 1e (MPES 2007) 6.0 19.9 3.3
Norway 3d (2008) 3.3 5.2 1.6
United Kingdom 1/2e (MPES 2007) 5.3 14.6 2.8
1=UNGASS 2008; 2=UNGASS 2010; 3=personal communication.
a=self-reported; b=TLS, venue based; c=RDS; d=health care system; e=population-based modelling.
n.a.= not available.
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Existing HIV prevalence estimates for MSM popula-
tions could be identified for 33 of the 38 EMIS countries
(see Table 1). No prevalence estimates were identified
for Austria, Cyprus, Ireland, Malta, and Turkey.
For four countries – Belgium, France, Sweden, and
Switzerland – we only identified published estimates
based on earlier national Internet surveys, methodo-
logically very similar to EMIS. Because of the use of the
same sampling methodology these four countries were
excluded from further comparison.
From the remaining 29 countries, estimates for seven
countries (Denmark, Germany, Greece, Luxemburg,
Netherlands, Norway, and United Kingdom) were based
on surveillance data and sophisticated (Germany, Neth-
erlands, UK) or relatively simple modelling approaches.
The simple approaches consisted of the number of diag-
nosed MSM in medical care plus an estimated number
of undiagnosed infections (25%) divided by 3% of the
adult male population (aged 15–64 years). The correl-
ation between these modelled estimates and EMIS esti-
mates for these seven countries was strong (R2=0.72; see
Figure 2).
One of the 22 countries with HIV prevalence studies
had an estimate based on self-reported HIV status. For
others, detailed information on methodology was not
always available. For six countries data were based on a
collaborative European study (SIALON I) using time lo-
cation sampling in six cities (Barcelona, Bratislava, Bu-
charest, Ljubljana, Prague, and Verona [7]), the other
estimates are based on respondent driven sampling,
snowball sampling, or other less formalized venue based
sampling methods. The correlation between the preva-
lence study estimates and the EMIS prevalence estimates
was high (R2=0.70; see Figure 3).
Among the countries with larger discrepancies were
countries with very small EMIS sample sizes (Macedo-
nia, Bosnia) and low prevalence in direct prevalence
studies. Discrepancies were also observed for some of
the cities participating in the SIALON I study. However,
if for these cities the EMIS prevalence estimates were
correlated with the proportion of already diagnosed HIV
infections in the study participants the correlation coeffi-
cient between the two measures further increased (R2
from 0.73 to 0.81; see Figure 4), with Bratislava as an
outlier for both approaches.
Table 1 presents the surveillance system-derived HIV
prevalence estimates among MSM for 29 countries to-
gether with a short description of the sources, the pro-
portion of those ever tested who were living with
diagnosed HIV, and the calculated SSD factor indicating
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Figure 1 Participation rates in EMIS across the 38 countries with samples >100.
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the discrepancy between HIV prevalence measured in
EMIS and pre-existing estimates.
More detailed EMIS data are presented in an Additional
file 1: Table S1 and include: (1) total number of partici-
pants per country; (2) number ever tested for HIV; (3)
number living with diagnosed HIV; (4) proportion of
those never tested or not tested within the last 12 months
who reported unprotected anal intercourse with any part-
ner of unknown or discordant HIV status.
Discussion
Self-reported prevalence rates of HIV diagnosis in a large
Internet convenience sample of European MSM correlate
strongly with prevalence estimates derived from direct
prevalence studies using different sampling methods. This
argues for at least partly similar self-selection biases in the
different types of studies. Discrepancies between EMIS
and pre-existing estimates can be due to:
 different time points of measurement - most
prevalence studies were conducted earlier than the
EMIS survey (e.g. up to six years earlier in Poland);
 measurement errors due to small sample sizes,
particularly in smaller countries and countries with
low estimated HIV prevalence among MSM (e.g.
Bosnia-Herzegovina, Macedonia);
 different self-selection biases in direct prevalence
studies and self-reported prevalence in an Internet
survey - this may apply particularly to countries
with high degrees of HIV-related stigma as it is
conceivable that in these countries MSM already
diagnosed with HIV may be less inclined to
participate in direct seroprevalence studies because
of concerns regarding confidentiality, while they
may be more inclined to participate in an
anonymous Internet survey.
 Of particular note, in four of five countries in which
self-reported HIV prevalence in EMIS samples is
lower than prevalence estimates from direct
prevalence studies, these studies used Time Location
Sampling in gay venues, suggesting that in those
countries MSM visiting such venues might have a
higher probability to be infected with HIV than
participants of an internet survey.
The discrepancy between EMIS prevalence and the
prevalence values derived from more sophisticated mod-
elling approaches like Multiparameter Evidence Synthe-
sis (MEPS) or back-calculation based on clinical staging
and CD4 cell count at HIV diagnosis in this analysis was
approximately 2 to 2.5-fold. This could mean that either
the size of the total MSM population is overestimated in
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the respective models or that HIV positive participants
are about two times as likely to participate in the EMIS
survey in the respective countries. The Netherlands are
an outlier in this regard with a calculated SSD of 3.3.
Apart from the quite high EMIS prevalence estimate of
19.7%, also other sample characteristics like the highest
median age of all samples argue for a possibly higher
self-selection bias for Dutch EMIS participants. A possible
explanation for a higher self-selection bias than other
neighbouring countries could be the high frequency of
Internet based behaviour surveys in the Netherlands (once
yearly), possibly resulting in a kind of survey fatigue which
may be more pronounced in younger, HIV negative or un-
tested MSM.
A more thorough analysis and discussion of the issue
of MSM population size and self-selection biases in
internet surveys is beyond the scope of this paper. We
would like to refer to another paper which compares
self-reported newly diagnosed HIV infections in national
EMIS samples and data on newly diagnosed HIV among
MSM reported in the national surveillance systems, in
which MSM population size estimations and how they
relate to survey-surveillance discrepancies are addressed
(Marcus U, et al.: Estimating the size of the MSM popu-
lations for 38 European countries by calculating the
survey-surveillance discrepancies (SSD) between self-
reported new HIV diagnoses from the European MSM
Internet Survey (EMIS) and surveillance-reported HIV
diagnoses among MSM in 2009. Submitted and under
review).
There are several limitations to this analysis. First, the
sample size of several national samples in EMIS was too
small to make reliable HIV prevalence estimates. Se-
condly, there is no agreed definition of MSM and the
size of the population is unknown for most countries.
This means we cannot be confident that the relative
prevalence rates from EMIS and specific prevalence
studies refer to similar proportions of the adult male
population. It is possible and conceivable that prevalence
rates e.g. in UK, Germany, and the Netherlands refer to
3% of the adult male population, while prevalence rates
in Poland, Romania, Bulgaria, Russia, and Ukraine refer
to 1% or 1.5% of the adult male population.
Conclusions
To summarize, EMIS, the first Pan-European MSM
Internet survey, is a study that allows triangulation of
data for almost all European countries. We can demon-
strate a high correlation between self-reported HIV
prevalence in EMIS and existing national prevalence
studies using different sampling methods, however, self-
reported prevalence in EMIS seems to be consistently
higher than prevalence in other types of studies. Taking
a likely systematic over-estimate into account, Pan-
European community based open access Internet sur-
veys can be cost-effective alternatives to national preva-
lence studies for generating comparable HIV prevalence
estimates. Determination of the undiagnosed fraction of
infections can better be achieved by studies collecting
biological samples and behavioural data. However, va-
riability of self-selection biases between studies in differ-
ent countries and using different sampling methods may
hamper cross-country comparisons of respective study
results.
Endnotes
aThis measure may only be an approximation to the
real prevalence because (a) the prevalence of undiag-
nosed HIV in those never tested may not be the same as
in those who have ever tested, and (b) some men whose
last HIV test was negative will have sero-converted since
that test.
bFor communication between ECDC and EU member
states on surveillance data, disease-specific contact
points are nominated. Usually these are the institutions
responsible for national infectious disease surveillance.
For verification of Russian data the Russian EMIS part-
ners have been contacted.
Additional file
Additional file 1: Table S1. Country data on EMIS sample size, number
ever tested for HIV, self-reported HIV prevalence, and proportion with
reported UAI risk in the previous 12 months among those who have
never tested for HIV. Sorting by increasing probability of underestimating
prevalence in the EMIS sample by self-reported prevalence (based on
proportion ever testing among respondents with UAI-risk in previous 12
months).
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